On March 30, 2020, AquaVenture Holdings Limited completed its previously announced merger (the “Merger”) with Amberjack Merger Sub Limited (“Merger Sub”), a subsidiary of Culligan International Company, a Delaware corporation (“Parent” or “Culligan”), pursuant to the Agreement and Plan of Merger, dated as of December 23, 2019, among Parent, Merger Sub and AquaVenture (the “Merger Agreement”). AquaVenture was the surviving corporation in the Merger and, as a result of the Merger, has become a subsidiary of Parent. In connection with the Merger, each of Anthony Ibarguen, Douglas Brown, Debra Coy, Hugh Evans, Paul Hanrahan, David Lincoln, Cyril Meduña, Richard Reilly and Timothy J. Whall, being all of the directors of AquaVenture as of immediately prior to the Effective Time, resigned from his or her respective position as a member of the Board of Directors of AquaVenture, and any committee thereof, effective as of the Effective Time. As contemplated by the Merger Agreement, the following individuals became directors of AquaVenture following the Merger: Samuel Allen Hamood and Andrew Kellogg. Samuel Allen Hamood. Mr. Hamood currently serves as Executive Vice President and Chief Financial Officer at Culligan and as the sole director of Merger Sub. Mr. Hamood joined Culligan in 2019. Prior to his time at Culligan, Mr. Hamood served as interim Chief Executive Officer and President of ATI Physical Therapy (“ATI”). Andrew Kellogg. Mr. Kellogg currently serves in the capacity of Vice President, Treasurer and Investor Relations of Culligan. Mr. Kellogg joined Culligan in 2019. Mr. Kellogg previously served as Treasurer and Director of Investor Relations of SunCoke Energy. Messrs. Hamood and Kellogg are not related to any officer or director of the Company. With respect to each of Messrs. Hamood and Kellogg, there are no arrangements or understandings between such director and any other persons pursuant to which he will serve as a director.